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Abstract 
The number and function of stem cells decline with aging, reducing the ability of stem cells 
to contribute to endogenous repair processes. Particularly, stemness property of stem 
cells is susceptible to age-related changes, including increased rates of apoptosis and 
senescence, and decreased efficiency of paracrine activity. Also, aging detrimentally 
affects the effectiveness of stem cell transplantation and the injection of the collected types 
of molecules released by them, leading to reduction in stem cell ability to contribute to 
endogenous repair processes. The repair capacity of stem cells in aged individuals may be 
improved by genetically reprogramming the stem cells to exhibit delayed senescence and 
enhanced regenerative properties. In this review, we describe critical genes and signaling 
pathways in stem cell aging, that are of interest for the cardiovascular system, and discuss 
ex vivo genetic modification approaches aimed at stem cell rejuvenation.  
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INTRODUCTION 
Patients with severe obstructive vascular disease, usually caused by atherosclerotic 
plaque narrowing of arteries are often aged and have tissue resident and circulating 
vascular stem/progenitor cells with diminished functions [1, 2]. These functional deficits 
may cause a poor angiogenic response to hypoxia or ischemia, with impaired collateral 
vessel formation and microcirculation [3]. Likewise with age, which is a major risk factor for 
cardiovascular disease, regenerative properties deteriorate and consequently resident 
stem/progenitor cells in elderly humans may have a decreased capacity for repair in 
response to tissue injury. Also in aged tissues, myogenic or angiogenic stem cells may 
transform into fibroblasts which contribute to enhanced fibrosis [4, 5]. These combined 
age-related deficits likely contribute to decreased muscle, weakened vessel regeneration 
after injury and facilitation of atherosclerosis and its sequelae in older individuals [6]. 
Replenishing stem cell function either by rejuvenating existing aging cells or transplanting 
stem/progenitor cells from donors capable of supplying the ischemic tissue with new 
vessels and preventing ischemic tissue damage, have been considered an appropriate 
therapy for this condition. In this review, we describe critical genes and signaling pathways 
in stem cell aging, that are of interest for the cardiovascular system, and discuss ex vivo 
genetic modification approaches aimed at stem cell rejuvenation. 
  
POTENTIAL OF STEM CELLS IN THE TREATMENT OF AGE-RELATED 
CARDIOVASCULAR DISEASES  
Diseases of aging, such as metabolic syndrome, diabetes, atherosclerosis, 
neurodegenerative diseases, osteoporosis and cancer, constitute a huge burden for all 
societies, both in terms of economics and quality of life. Despite contemporary medical 
treatments, heart failure remains a major cause of morbidity and mortality in old people of 
developed countries  [7]. Both type 1 and type 2 diabetes are associated with aging and 
increased risk of micro- and macrovascular disease, which can lead to ischemic heart 
disease, heart failure and critical limb ischemia. Hyperglycemia leads to and aggravates 
the reduction of blood flow in cardiovascular tissues. This is believed to occur in a cascade 
in which ischemia induces oxidative stress initiating fibrosis and, thereby, increasing the 
thickness of microvasculature walls [8]. Some consequences of oxidative stress-
associated hyperglycemia include: alteration of energy metabolism, organ dysfunction, 
limited exercise tolerance, and greatly increased vulnerability to a super-imposed ischemic 
stressor (i.e., following atherosclerotic occlusion of a main artery). Valid therapeutic 
strategies that repair damaged heart muscle and ischemic tissue have not yet been 
developed. Heart transplantation remains the only effective remedy for heart failure. 
Meanwhile critical limb ischemia represents a major cause of diabetes-associated 
morbidity [9], still representing the most common cause of amputation in diabetic patients.  
Recent seminal reports have indicated that the adult heart is self-healing and self-
renewing. Specifically, these studies demonstrated that there is a pool of resident cardiac 
stem cells (CSCs) that are clonogenic and multipotent and are capable of differentiating 
into new blood vessels or into new myocytes [10]. This suggests the opportunity to boost 
the endogenous regenerative approach to complement other treatments (e.g., stem cell 
transplantation) that facilitate myocardial repair. However, despite recent progress in 
applying the approaches of regenerative medicine to the treatment of these diseases, valid 
strategies aimed at repairing the infarcted heart and, in general, at treating end-organ 
ischemia continue to be elusive [11].  
In recent years, efforts to use the alternative strategies of regenerative medicine as for 
treating cardiovascular disease have been partially successful. The limitations, still not 
completely understood, include: 1) inadequate recruitment of circulating or resident cardiac 
stem cells; 2) poor capability of adult stem cells to differentiate into cardiomyocytes; 3) 
elevated mortality of transplanted stem cells; 4) anomalous electro-mechanical behavior of 
transplanted cells after stimulation and the eventual onset of arrhythmias; 5) formation of 
new heart tissue structure differing from that of normal heart; and 6) diminished function of 
both resident and circulating stem/progenitor cells with the onset of aging and age-related 
cardiovascular disease.  
 
BOUNDARIES OF STEM CELLS IN THE TREATMENT OF AGE-RELATED 
CARDIOVASCULAR DISEASE   
The difficulty in providing functionally competent autologous stem cells isolated  from aged 
patients with disease, that are specifically effective in myocardial repair, and in the 
engraftment and survival of transplanted stem cells in the harmful microenvironment of 
host tissue, represent major obstacle for stem cell therapy in aged people. The capacity of 
organs, including the heart, to self-repair decreases with age and becomes compromised 
after ischemic injury, partially resulting from the reduced functional capabilities of stem 
cells [1]. Aging is a major risk factor for cardiovascular disease. With the onset of age-
related cardiovascular disease, which often occurs secondarily to atherosclerosis, the 
function of both resident and circulating stem/progenitor cells and their paracrine activities 
is diminished [12]. Furthermore, aging and risk factors might largely affect endogenous 
cardioprotective pathways [13]. Stem cells are susceptible to age-related changes, 
including increased rates of apoptosis and senescence, that reduce their ability to 
contribute to endogenous repair processes. Furthermore, with aging the effectiveness of 
stem cells after transplantation diminishes [14]. Therefore, concerns remain with regard to 
the  potentially lower potency of stem cells from patients, in whom aging and/or disease 
may lead to a poor quality of the stem cell preparation, as aging or the disease may impair 
the source for stem cell or create a hostile microenvironment for implanted stem cells [14]. 
The combination of these disease and age-related deficits may contribute to decreased 
muscle and vessel regeneration after injury and facilitate the development of 
atherosclerosis and its sequelae in aged individuals. In this context, an appropriate therapy 
for age-related vascular disease may be to replenish stem cell function and the collected 
types of molecules released by the stem cells, by rejuvenating existing cells or 
transplanting functional competent stem/progenitor cells or injecting their cellular products 
that will supply the ischemic tissue with new vessels to prevent ischemic tissue damage. 
  
CRITICAL GENES AND SIGNALING PATHWAYS IN STEM CELL AGING AND 
REJUVENATION 
 
Although relatively little has been accomplished for “turning back the clock” in the 
myocardial context, there are signaling pathways that seem connected to reversing the 
cardiac senescence. For example, experimental activation of Notch restored “youthful” 
myogenic responses to satellite muscle cells isolated from 70-year-old humans, rendering 
them similar to cells from 20-year-old humans [15]. Pim-1 kinase is another example of 
antisenescence pathway that works in the context of cardiac stem cells. Pim-1 enhances 
proliferation [16], metabolic activity [17] and differentiation [18, 19] of CSCs and 
mesenchymal stem cells (MSCs) in neovessels and new myocytes. Pim-1 also serves as a 
prosurvival role by preserving mitochondrial integrity [20] and antagonizing intrinsic 
apoptotic cascades [21].  Moreover, Pim-1 preserves telomere length and telomerase 
activity of CSCs [17]. Mohsin and collegues have recently showed that genetic 
modification of aged human cardiac progenitor cells (CPCs) with Pim-1 kinase results in 
remarkable rejuvenation of them, with enhanced proliferation, increased telomere lengths, 
and decreased susceptibility to replicative senescence [22]. Manipulation of the telomere-
telomerase axis was suggested in 1998, when 2 different human cell lines, retinal pigment 
epithelial cells and foreskin fibroblasts, were transfected with vectors encoding for human 
telomerase catalytic subunit. Since then much research has been done on the heart, 
telomeres and telomerase. We recently identified a subpopulation of adipose tissue–
derived mesenchymal stromal cells MSCs (AT-MSCs) that expresses high levels of the 
catalytic subunit of telomerase (ie, telomerase reverse transcriptase or TERT) and 
myocardin (MYOCD) [23, 24]. AT-MSCs have been shown to contain a population of adult 
multipotent mesenchymal stem cells with high cardiovascular regenerative potential [23, 
25-28]. MYOCD is a key regulator of cardiovascular myogenic development [23, 29, 30] 
and acts as a nuclear transcription cofactor for myogenic genes, as well as genes involved 
in muscle regeneration and protection against apoptosis [31, 32]. Telomerase maintains 
telomere length, contributes to cell survival and proliferation, and prevents cellular 
senescence [33, 34]. We have shown that AT-MSCs that co-express TERT and MYOCD 
have increased endogenous levels of octamer-binding transcription factor 4 (Oct-4), 
MYOCD, myocyte-specific enhancer factor 2c (Mef2c), and homeobox protein NKx2.5. 
These observations suggest that TERT and MYOCD may act together to enhance 
cardiovascular myogenic development [24, 35]. 
 
 
EX VIVO GENE MODIFICATION APPROACH FOR STEM CELL REJUVENATION 
Although traditional in vivo gene delivery approach via direct injection of viral vectors by 
attaching the delivery vector to the scaffold [36], is still a candidate strategy in laboratory-
based trials, the most frequently investigated cell engineering method to augment 
regeneration of old and diseased cardiovascular tissues, to date, is ex vivo cell-based 
gene therapy. This therapy typically relies on transplanting cells, such as stem cells, 
lymphocytes, fibroblasts, or – alternatively – the cells of interest, that are removed from the 
body and injected after therapeutic transgene modifications [16, 37]. This ex vivo approach 
allows for targeting of specific cells for gene delivery, supplies rejuvenated cells that may 
directly participate in the regenerative process, and avoids the safety risks of directly 
injecting viral vectors or transfection reagents in vivo. This approach, however, involves an 
extra step to manipulate and expand cells in tissue culture, and has the risk of 
contamination. Additionally, the ex vivo approach does not eliminate the possibility of 
retroviral vectors causing insertional activation of other genes, the over-expression of 
which may cause cancer, as experienced when using ex vivo gene therapy for the 
treatment of children with X-linked severe combined immune deficiency [38]. Progress in 
the field of gene therapy has been limited by safety concerns related to delivery vectors. 
Genetically modified cells are potentially able to provide a stable source of rejuvenating 
factors at a level that is sufficient to elicit a biological response. Autologous cells may also 
be used in this approach via the isolation of a small number of differentiated adult cells or 
stem cells, followed by in vitro expansion to produce an appropriate supply. The cells may 
naturally secrete or be genetically modified in vitro to overexpress the rejuvenating factor, 
either transiently or permanently. After their genetic modification, the cells are allowed to 
grow in vitro and increase in number, so as to synthesize and secrete the desired 
rejuvenating factors at the site where they have been transplanted. Recently, our research 
group examined the interplay in mesenchymal stem cells (MSCs) between two genes, one 
coding for the catalytic subunit of telomerase (i.e., telomerase reverse transcriptase or 
TERT), that has antisenescence properties, the other coding for myocardin (MYOCD), a 
nuclear transcription cofactor for myogenic genes, as well as for genes involved in muscle 
regeneration and protection against apoptosis [14, 23, 24, 35] . We have examined the role 
of TERT and MYOCD  in the conversion of aged MSCs to rejuvenated anti-apoptotic, 
promyogenic stem cells [14]. We have shown that the delivery of the TERT and MYOCD 
genes can restore MSCs from aged mice by increasing cell survival, proliferation, and 
smooth muscle myogenic differentiation in vitro [14]. Furthermore, we have demonstrated 
the therapeutic efficacy of these rejuvenated cells in an in vivo hindlimb ischemia model 
[14]. 
 LENTIVIRAL AND NON-LENTIVIRAL VECTORS FOR GENE DELIVERY INTO STEM 
CELLS 
The introduction or the overexpression of rejuvenating genes in stem cells can be 
performed by using viral or non-viral vectors. In the choice of using viral vectors, important 
experimental variables for a successful gene therapy include Multiplicity Of Infection (MOI) 
time length for viral incubation and medium used for viral incubation. An optimal 
combination of such experimental conditions would increase gene transfer efficiency and 
possibly obviate the need for selective antibiotic-based enrichment and long-term culture, 
which may contribute to senescence or compromise the long-term engraftment efficiency 
and/or multipotency of grafted cells [39]. In addition, by increasing gene transfer efficiency, 
fewer cells may be required to achieve a therapeutic effect. This justifies the use of 
lentiviral vectors for transducing adult stem cells, by virtue of their ability to transduce both 
dividing and non-dividing cells and their relative ease of use and comparable nature to 
adeno-associated viral (AAV) vectors, which are clinically preferred. For the transduction 
of adult stem cells, lentivirus-based systems are virtually ideal, since they overcome most 
problems, including the short duration of gene expression and the occurrence of significant 
inflammatory responses, which plague other types of gene vectors (such as 
adenoviruses). Lentiviruses are a subgroup of retroviruses that include the human type 1 
immunodeficiency virus (HIV). While retroviral systems are inefficient in transducing non-
dividing or slowly dividing cells, lentivirus-based vectors, after being pseudotyped with 
vesicular stomatitis virus glycoprotein G (VSV-G) (i.e., using the glycoprotein envelope 
from the vesicular stomatitis virus to package recombinant retroviruses) [40], can mediate 
genome integration into both non-dividing and dividing cells. There is evidence that 
lentiviral vectors can also transduce more primitive, quiescent progenitors with stable 
transgene integration  [41]. In comparison with other retroviral vectors, lentiviral systems 
allow the immediate transduction without prior expansion, or with growth factor stimulation 
for only short exposure times. Compared with adenoviral vectors, lentiviral vectors also 
offer the major advantages of causing little or no disruption of the target cells and of not 
promoting any inflammatory response [42]. AAV vectors represent an alternate type of 
vector that may also be used for long-term transgene expression in the heart through cell-
based therapy [43]. Like lentiviruses, AAV can stably integrate into the host genome 
providing long-term transgene expression, with a minimum inflammatory response. 
However, AAV can cause insertional mutagenesis and can only carry genes which are 
less than 5 kb [44]. A possible drawback of the use of lentiviral and AAV vectors for 
delivering genes that encode for growth factors might be that they can cause a chronic 
overexpression of the protein, with an uncertain therapeutic effect. Short-term gene 
expression of the rejuvenating factor gene would be desirable if the goal is to deliver an 
anti-senescent protein, such as TERT, without neoplastic modification or immortalization of 
the stem cell target. On the contrary, long-term expression would be preferable if the goal 
is to express membrane proteins such as receptors for growth factors that require stable 
expression, or promyogenic transcription factors. Possible strategies to induce short-term 
gene expression of the transgene include plasmid transfection or the use of adenoviral 
vectors [45]. Limitations of these strategies are the low transfection efficiency with 
plasmids and the immunogenic response of the host with adenoviruses. 
 
PERSPECTIVE AND OPEN QUESTIONS 
Ex-vivo genetic modification of stem cells may offer an effective strategy for rejuvenating 
aged stem cells and diseased organs. Further studies, particularly more bench-to-bedside 
translational work, are needed to clarify the impact of aging and cardiovascular disease 
on stem cell generation and help identifying the genetic as well as pharmacological tools 
that can rescue aged/sick stem cells as part of personalized medicine. In particular, future 
research in this field should aim at achieving the following goals: 
 (1) add fundamental novel information on the pathobiology of aged stem cells, isolated 
from aged, atherosclerosis-prone or cardiac infarct patients; (2) design new protocols for 
aged stem cell rejuvenation capable to lead to improved preparation and clinical 
application of stem cells harvested from aged tissues and their products, and (3) design 
new protocols for in vivo transplantation of rejuvenated stem cell therapies.  
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